# Novel ADC Boosts Survival in Pretreated Endometrial Cancer

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/esmofuturefocus/123805) · 2026-11-10 · Medicine
Page: https://themorning.science/story/novel-adc-boosts-survival-in-pretreated-endometrial-cancer-6431379a4bd40014
Kind: research · Impact: medium

## In brief

- Results from the TroFuse-005 trial were presented at the annual ESMO congress.
- The investigational antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) significantly improved survival in pretreated endometrial cancer, according to the trial results.

## Why it matters

It reports a survival benefit from an investigational drug in a patient group with limited treatment options after prior therapy, which may inform future endometrial cancer treatment research.

## Coverage

- [Novel ADC Boosts Survival in Pretreated Endometrial Cancer](https://www.medpagetoday.com/meetingcoverage/esmofuturefocus/123805) — MedPageToday.com - medical news for physicians, 2026-11-10

Tags: oncology, endometrial cancer, antibody-drug conjugate, clinical trial, sacituzumab tirumotecan

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science